SPWM
LCTX icon

Straight Path Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Straight Path Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,200
Closed -$14.7K – 98
2024
Q3 		$14.7K Hold
16,200
– – 0.01% 98
2024
Q2 		$16.2K Hold
16,200
– – 0.01% 96
2024
Q1 		$24K Hold
16,200
– – 0.01% 90
2023
Q4 		$17.7K Hold
16,200
– – 0.01% 90
2023
Q3 		$19.1K Hold
16,200
– – 0.01% 80
2023
Q2 		$22.8K Hold
16,200
– – 0.02% 77
2023
Q1 		$24.3K Hold
16,200
– – 0.02% 73
2022
Q4 		$19K Hold
16,200
– – 0.02% 71
2022
Q3 		$18K Hold
16,200
– – 0.02% 73
2022
Q2 		$26K Hold
16,200
– – 0.03% 72
2022
Q1 		$25K Hold
16,200
– – 0.02% 69
2021
Q4 		$40K Buy
+16,200
New +$37.9K 0.03% 77

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Straight Path Wealth Management's LCTX Position: Q4 2024 in Review

Straight Path Wealth Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2024, closing a stake of 16,200 shares — an estimated $14.7K sold.

Straight Path Wealth Management first reported a position in LCTX in Q4 2021 and held it in 12 quarters. The position peaked at $40K in Q4 2021. 126 funds tracked by Wall St. Rank hold LCTX as of Q4 2024.

  • Straight Path Wealth Management reported no remaining Lineage Cell Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Straight Path Wealth Management sold 16,200 Lineage Cell Therapeutics shares in Q4 2024, an estimated $14.7K.
  • Straight Path Wealth Management first reported a position in Lineage Cell Therapeutics in Q4 2021 and held it in 12 quarters.
  • Straight Path Wealth Management's Lineage Cell Therapeutics position peaked at $40K in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2024.

Based on Straight Path Wealth Management's 13F filing for Q4 2024, filed 6 Feb 2025.